459 related articles for article (PubMed ID: 34075567)
1. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Cerulli Irelli E; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Gangitano M; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Morano A; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
Drugs Aging; 2022 Apr; 39(4):297-304. PubMed ID: 35344198
[TBL] [Abstract][Full Text] [Related]
5. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
[TBL] [Abstract][Full Text] [Related]
7. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
[TBL] [Abstract][Full Text] [Related]
8. Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study.
D'Souza W; Alsaadi T; Montoya J; Carreño M; Di Bonaventura C; Mohanraj R; Yamamoto T; McMurray R; Shastri O; Villanueva V;
Seizure; 2022 Aug; 100():56-66. PubMed ID: 35777333
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study.
Mai J; Li H; He Y; Huang T; Lin C; Lan S; Xiao X; He S; Lu X; Chen L; Li B; Luo X; Wang H; Liao J; Cao D
Seizure; 2024 Apr; 117():44-49. PubMed ID: 38308908
[TBL] [Abstract][Full Text] [Related]
10. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
[TBL] [Abstract][Full Text] [Related]
11. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
12. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
13. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice.
Trinka E; Alsaadi T; Goji H; Maehara T; Takahashi S; Jacobs J; Renna R; Gil-López FJ; McMurray R; Sáinz-Fuertes R; Villanueva V
Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
[TBL] [Abstract][Full Text] [Related]
16. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
[TBL] [Abstract][Full Text] [Related]
17. Preliminary Asian experience of using perampanel in clinical practice.
Chiang HI; Lim SN; Hsieh HY; Cheng MY; Chang CW; Johnny Tseng WE; Li HT; Lin CY; Wu T
Biomed J; 2017 Dec; 40(6):347-354. PubMed ID: 29433838
[TBL] [Abstract][Full Text] [Related]
18. The real-world effectiveness and safety of perampanel in Europe: A scoping review.
Estévez-María JC; Garamendi-Ruiz I
Epilepsy Behav; 2022 Sep; 134():108777. PubMed ID: 35816832
[TBL] [Abstract][Full Text] [Related]
19. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.
Villanueva V; D'Souza W; Goji H; Kim DW; Liguori C; McMurray R; Najm I; Santamarina E; Steinhoff BJ; Vlasov P; Wu T; Trinka E;
J Neurol; 2022 Apr; 269(4):1957-1977. PubMed ID: 34427754
[TBL] [Abstract][Full Text] [Related]
20. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]